Johnson & Johnson (JNJ) Tops Q2 EPS by 4c; Boosts FY15 EPS Outlook

Johnson & Johnson (NYSE: JNJ) reported Q2 EPS of $1.71, $0.04 better than the analyst estimate of $1.67. Revenue for the quarter came in at $17.8 billion versus the consensus estimate of $17.76 billion.

"Our solid sales and earnings results in the quarter reflect the strong underlying growth we're seeing across the enterprise," said Alex Gorsky, Chairman and Chief Executive Officer. "Our diverse portfolio and scale are enabling this performance, and we've continued to invest in building a robust enterprise pipeline that will drive our growth over the long term. Our passion to deliver transformational new medicines and products reflects the ongoing commitment of our dedicated employees to improve health and well-being."

Guidance:

Johnson & Johnson sees FY2015 EPS of $6.10 - $6.20, versus the consensus of $6.14 and $6.04 - $6.19 previously expected by the company.

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.

You May Also Be Interested In

• Grainger (GWW) Tops Q1 EPS by 2c, provides guidance
• California Water Service (CWT) Tops Q1 EPS by 111c
• Union Pacific (UNP) Tops Q1 EPS by 18c